A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
We're looking into a new medicine called efgartigimod PH20 SC for young people aged 2 to 17 who have a condition affecting their muscles called generalised Myasthenia Gravis (gMG). This study aims to find the most effective and safest dose for children. We'll be giving participants injections of the medicine and closely watching how their bodies react, how much of the medicine is in their system, and if there are any side effects. The main goal is to figure out the right amount of medicine for children with gMG. Those who complete the main study might have the option to continue with the medicine in a follow-up study.
En un coup d'œil
De quoi parle cette étude ?
This research is looking at a new treatment called efgartigimod PH20 SC for children and teenagers between 2 and 17 years old who have generalised Myasthenia Gravis (gMG). gMG is a condition that causes muscle weakness. Even though you might already be taking other medicines for your gMG, this study is for those who haven't found enough relief from their current treatments.
The main purpose of this study is to understand how this new medicine works in young people. We want to learn how the body uses and processes the medicine, what effects it has, and importantly, to make sure it's safe and well-tolerated. Finding the right dose for children is really important because medicines can affect children differently than adults.
Over a period of up to 14 weeks, participants will receive the efgartigimod PH20 SC medicine as injections. The research team will regularly check on their health and monitor for any side effects. At the end of these 14 weeks, if the medicine is helping and suitable, some participants might be able to continue receiving the treatment in a longer-term follow-up study, which is called an open-label extension study.
Points clés
- This study is for children aged 2-17 with generalised Myasthenia Gravis.
- It's testing a new injection called efgartigimod PH20 SC.
- The main goals are to find the right dose and check its safety.
- Participants will have regular check-ups over 14 weeks.
- Vous pouvez arrêter de participer à tout moment.
- Your child will still take their current MG medicines if they are on a stable dose.
Qui peut être éligible ?
To join this study, a young person must be between 2 and 17 years old. They need to have been diagnosed with generalised Myasthenia Gravis, and doctors must have found specific antibodies in their blood. Also, their current treatments for Myasthenia Gravis shouldn't be working well enough for them, but they need to be on a steady dose of these existing medicines for at least a month before joining.
There are also some things that would mean someone cannot take part. For example, if a young woman could become pregnant, she cannot be pregnant or breastfeeding, and must agree to use effective birth control during the study. Participants cannot have certain other medical conditions or have had particular treatments recently, like some vaccinations, or surgery on their thymus gland in the last three months.
The study also cannot include anyone who has worsening muscle weakness due to an infection or another medicine, or if their Myasthenia Gravis didn't improve after a specific treatment called plasma exchange (PLEX). If they've had cancer, they usually need to have been free of it for at least three years, though some types of skin cancer might be an exception.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Is your child aged between 2 and 17 years old?
- Does your child have a diagnosis of generalised Myasthenia Gravis confirmed by a blood test?
- Are your child's current Myasthenia Gravis medications not fully controlling their symptoms, but they have been on a stable dose for at least a month?
- Is your child not currently pregnant, breastfeeding, or planning to become pregnant during the study?
- Has your child not had thymus gland surgery in the last 3 months?
- Does your child not have new muscle weakness from an infection or other medication?
En quoi consiste la participation ?
If you decide to take part, you or your child will be in the study for up to 14 weeks. During this time, they will receive injections of the study medicine, efgartigimod PH20 SC. The research team will arrange for regular check-ups to see how the medicine is affecting your child, track how much of it is in their body, and look for any side effects. This involves visits to the clinic for assessments and monitoring. After the 14 weeks, if suitable, there might be an option to continue the treatment in a follow-up study.
Risques et avantages potentiels
Locations (22)
- Carolinas HealthCare System Neurosciences Institute - NeurologyCode postal vérifiéCharlotte, États-Unis· Actif, mais pas en recrutement
- Neurology Rare Disease CenterCode postal vérifiéDenton, United States· Actif, mais pas en recrutement
- Université de VirginieCode postal vérifiéCharlottesville, United States· Actif, mais pas en recrutement
- Royal Children's Hospital MelbourneApproximatifMelbourne, Australie· Recrutement
- Sydney Children's HospitalCode postal vérifiéRandwick, Australia· Recrutement
- UZ GentCode postal vérifiéGand, Belgique· Recrutement
- Childrens Hospital of Eastern OntarioCode postal vérifiéOttawa, Canada· Recrutement
- Fakultni nemocnice BrnoCode postal vérifiéBrno, Tchéquie· Recrutement
- Fakultni nemocnice OstravaCode postal vérifiéOstrava, Czechia· Recrutement
- AP-HM- Hôpital de La TimoneCode postal vérifiéMarseille, France· Recrutement
- Universitätsklinikum EssenCode postal vérifiéEssen, Allemagne· Recrutement
- Hadassah Medical Center- Ein KeremCode postal vérifiéJerusalem, Israel· Recrutement
Questions fréquentes
What is generalised Myasthenia Gravis?
It's a condition that causes muscles to become weak and tired, making everyday tasks harder.
What is efgartigimod PH20 SC?
It's a new medicine being tested as an injection for people with generalised Myasthenia Gravis.
Combien de temps durera l'étude ?
Each participant will be in the main part of the study for up to 14 weeks.
Will my child still take their usual Myasthenia Gravis medicines?
Yes, your child will likely stay on their usual medicines, but these need to be at a stable dose before the study starts.
Puis-je quitter l'étude à tout moment ?
Yes, you can choose to withdraw from the study at any point, and it won't affect your child's regular medical care.
Comment en savoir plus
Sabine Coppieters, MD
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.